Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

BACKGROUND: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective. Nevertheless, immunocompromised participants were excluded from randomized controlled clinical trials. This study evaluates the efficacy and safety of the Pfizer/BioNTech BNT162b2 (BNT162b...

Descripción completa

Detalles Bibliográficos
Autores principales: De Placido, Pietro, Pietroluongo, Erica, De Angelis, Carmine, Tafuro, Margherita, Barraco, Chiara, Giannatiempo, Rosa, Buonaiuto, Roberto, Schettini, Francesco, Iervolino, Anna, Vozzella, Emilia Anna, Giuliano, Mario, Bianco, Roberto, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437636/
https://www.ncbi.nlm.nih.gov/pubmed/36059663
http://dx.doi.org/10.3389/fonc.2022.951026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437636/
https://www.ncbi.nlm.nih.gov/pubmed/36059663
http://dx.doi.org/10.3389/fonc.2022.951026

Ejemplares similares